Report Detail

Service & Software Global Bispecific Antibody Technology Platform Market Growth (Status and Outlook) 2022-2028

  • RnM4489265
  • |
  • 02 September, 2022
  • |
  • Global
  • |
  • 120 Pages
  • |
  • LPI(LP Information)
  • |
  • Service & Software

The global market for Bispecific Antibody Technology Platform is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Bispecific Antibody Technology Platform market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Bispecific Antibody Technology Platform market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Bispecific Antibody Technology Platform market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Bispecific Antibody Technology Platform market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Bispecific Antibody Technology Platform players cover Sanofi, Roche, WuXi Biologics, Merus and Biomunex, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Bispecific Antibody Technology Platform market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Bispecific Antibody Technology Platform market, with both quantitative and qualitative data, to help readers understand how the Bispecific Antibody Technology Platform market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Bispecific Antibody Technology Platform market and forecasts the market size by Type (IgG-like Bispecific Antibody Platform and Non IgG-like Bispecific Antibody Platform,), by Application (Tumor Disease, Hemophilia, Eye Disease and Other), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
IgG-like Bispecific Antibody Platform
Non IgG-like Bispecific Antibody Platform

Segmentation by application
Tumor Disease
Hemophilia
Eye Disease
Other

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Sanofi
Roche
WuXi Biologics
Merus
Biomunex
Alphamab Oncology
EPIMAB BIOTHERAPEUTICS, INC
Biocytogen
Lonza
Abbott
Amgen
Innovent
Epimab
Keymed
Selexis
SYNIMMUNE
F-star
Zymeworks Inc
Creative Biolabs
ImmunoPrecise
CytomX Therapeutics, Inc.

Chapter Introduction
Chapter 1: Scope of Bispecific Antibody Technology Platform, Research Methodology, etc.
Chapter 2: Executive Summary, global Bispecific Antibody Technology Platform market size and CAGR, Bispecific Antibody Technology Platform market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Bispecific Antibody Technology Platform revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Bispecific Antibody Technology Platform revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Bispecific Antibody Technology Platform market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, Roche, WuXi Biologics, Merus, Biomunex, Alphamab Oncology, EPIMAB BIOTHERAPEUTICS, INC, Biocytogen and Lonza, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Bispecific Antibody Technology Platform Market Size 2017-2028
    • 2.1.2 Bispecific Antibody Technology Platform Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Bispecific Antibody Technology Platform Segment by Type
    • 2.2.1 IgG-like Bispecific Antibody Platform
    • 2.2.2 Non IgG-like Bispecific Antibody Platform
  • 2.3 Bispecific Antibody Technology Platform Market Size by Type
    • 2.3.1 Bispecific Antibody Technology Platform Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Bispecific Antibody Technology Platform Market Size Market Share by Type (2017-2022)
  • 2.4 Bispecific Antibody Technology Platform Segment by Application
    • 2.4.1 Tumor Disease
    • 2.4.2 Hemophilia
    • 2.4.3 Eye Disease
    • 2.4.4 Other
  • 2.5 Bispecific Antibody Technology Platform Market Size by Application
    • 2.5.1 Bispecific Antibody Technology Platform Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Bispecific Antibody Technology Platform Market Size Market Share by Application (2017-2022)

3 Bispecific Antibody Technology Platform Market Size by Player

  • 3.1 Bispecific Antibody Technology Platform Market Size Market Share by Players
    • 3.1.1 Global Bispecific Antibody Technology Platform Revenue by Players (2020-2022)
    • 3.1.2 Global Bispecific Antibody Technology Platform Revenue Market Share by Players (2020-2022)
  • 3.2 Global Bispecific Antibody Technology Platform Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Bispecific Antibody Technology Platform by Regions

  • 4.1 Bispecific Antibody Technology Platform Market Size by Regions (2017-2022)
  • 4.2 Americas Bispecific Antibody Technology Platform Market Size Growth (2017-2022)
  • 4.3 APAC Bispecific Antibody Technology Platform Market Size Growth (2017-2022)
  • 4.4 Europe Bispecific Antibody Technology Platform Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Bispecific Antibody Technology Platform Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Bispecific Antibody Technology Platform Market Size by Country (2017-2022)
  • 5.2 Americas Bispecific Antibody Technology Platform Market Size by Type (2017-2022)
  • 5.3 Americas Bispecific Antibody Technology Platform Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Bispecific Antibody Technology Platform Market Size by Region (2017-2022)
  • 6.2 APAC Bispecific Antibody Technology Platform Market Size by Type (2017-2022)
  • 6.3 APAC Bispecific Antibody Technology Platform Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Bispecific Antibody Technology Platform by Country (2017-2022)
  • 7.2 Europe Bispecific Antibody Technology Platform Market Size by Type (2017-2022)
  • 7.3 Europe Bispecific Antibody Technology Platform Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Bispecific Antibody Technology Platform by Region (2017-2022)
  • 8.2 Middle East & Africa Bispecific Antibody Technology Platform Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Bispecific Antibody Technology Platform Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Bispecific Antibody Technology Platform Market Forecast

  • 10.1 Global Bispecific Antibody Technology Platform Forecast by Regions (2023-2028)
    • 10.1.1 Global Bispecific Antibody Technology Platform Forecast by Regions (2023-2028)
    • 10.1.2 Americas Bispecific Antibody Technology Platform Forecast
    • 10.1.3 APAC Bispecific Antibody Technology Platform Forecast
    • 10.1.4 Europe Bispecific Antibody Technology Platform Forecast
    • 10.1.5 Middle East & Africa Bispecific Antibody Technology Platform Forecast
  • 10.2 Americas Bispecific Antibody Technology Platform Forecast by Country (2023-2028)
    • 10.2.1 United States Bispecific Antibody Technology Platform Market Forecast
    • 10.2.2 Canada Bispecific Antibody Technology Platform Market Forecast
    • 10.2.3 Mexico Bispecific Antibody Technology Platform Market Forecast
    • 10.2.4 Brazil Bispecific Antibody Technology Platform Market Forecast
  • 10.3 APAC Bispecific Antibody Technology Platform Forecast by Region (2023-2028)
    • 10.3.1 China Bispecific Antibody Technology Platform Market Forecast
    • 10.3.2 Japan Bispecific Antibody Technology Platform Market Forecast
    • 10.3.3 Korea Bispecific Antibody Technology Platform Market Forecast
    • 10.3.4 Southeast Asia Bispecific Antibody Technology Platform Market Forecast
    • 10.3.5 India Bispecific Antibody Technology Platform Market Forecast
    • 10.3.6 Australia Bispecific Antibody Technology Platform Market Forecast
  • 10.4 Europe Bispecific Antibody Technology Platform Forecast by Country (2023-2028)
    • 10.4.1 Germany Bispecific Antibody Technology Platform Market Forecast
    • 10.4.2 France Bispecific Antibody Technology Platform Market Forecast
    • 10.4.3 UK Bispecific Antibody Technology Platform Market Forecast
    • 10.4.4 Italy Bispecific Antibody Technology Platform Market Forecast
    • 10.4.5 Russia Bispecific Antibody Technology Platform Market Forecast
  • 10.5 Middle East & Africa Bispecific Antibody Technology Platform Forecast by Region (2023-2028)
    • 10.5.1 Egypt Bispecific Antibody Technology Platform Market Forecast
    • 10.5.2 South Africa Bispecific Antibody Technology Platform Market Forecast
    • 10.5.3 Israel Bispecific Antibody Technology Platform Market Forecast
    • 10.5.4 Turkey Bispecific Antibody Technology Platform Market Forecast
    • 10.5.5 GCC Countries Bispecific Antibody Technology Platform Market Forecast
  • 10.6 Global Bispecific Antibody Technology Platform Forecast by Type (2023-2028)
  • 10.7 Global Bispecific Antibody Technology Platform Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Sanofi
    • 11.1.1 Sanofi Company Information
    • 11.1.2 Sanofi Bispecific Antibody Technology Platform Product Offered
    • 11.1.3 Sanofi Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Sanofi Main Business Overview
    • 11.1.5 Sanofi Latest Developments
  • 11.2 Roche
    • 11.2.1 Roche Company Information
    • 11.2.2 Roche Bispecific Antibody Technology Platform Product Offered
    • 11.2.3 Roche Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Roche Main Business Overview
    • 11.2.5 Roche Latest Developments
  • 11.3 WuXi Biologics
    • 11.3.1 WuXi Biologics Company Information
    • 11.3.2 WuXi Biologics Bispecific Antibody Technology Platform Product Offered
    • 11.3.3 WuXi Biologics Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 WuXi Biologics Main Business Overview
    • 11.3.5 WuXi Biologics Latest Developments
  • 11.4 Merus
    • 11.4.1 Merus Company Information
    • 11.4.2 Merus Bispecific Antibody Technology Platform Product Offered
    • 11.4.3 Merus Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Merus Main Business Overview
    • 11.4.5 Merus Latest Developments
  • 11.5 Biomunex
    • 11.5.1 Biomunex Company Information
    • 11.5.2 Biomunex Bispecific Antibody Technology Platform Product Offered
    • 11.5.3 Biomunex Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Biomunex Main Business Overview
    • 11.5.5 Biomunex Latest Developments
  • 11.6 Alphamab Oncology
    • 11.6.1 Alphamab Oncology Company Information
    • 11.6.2 Alphamab Oncology Bispecific Antibody Technology Platform Product Offered
    • 11.6.3 Alphamab Oncology Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Alphamab Oncology Main Business Overview
    • 11.6.5 Alphamab Oncology Latest Developments
  • 11.7 EPIMAB BIOTHERAPEUTICS, INC
    • 11.7.1 EPIMAB BIOTHERAPEUTICS, INC Company Information
    • 11.7.2 EPIMAB BIOTHERAPEUTICS, INC Bispecific Antibody Technology Platform Product Offered
    • 11.7.3 EPIMAB BIOTHERAPEUTICS, INC Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 EPIMAB BIOTHERAPEUTICS, INC Main Business Overview
    • 11.7.5 EPIMAB BIOTHERAPEUTICS, INC Latest Developments
  • 11.8 Biocytogen
    • 11.8.1 Biocytogen Company Information
    • 11.8.2 Biocytogen Bispecific Antibody Technology Platform Product Offered
    • 11.8.3 Biocytogen Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Biocytogen Main Business Overview
    • 11.8.5 Biocytogen Latest Developments
  • 11.9 Lonza
    • 11.9.1 Lonza Company Information
    • 11.9.2 Lonza Bispecific Antibody Technology Platform Product Offered
    • 11.9.3 Lonza Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Lonza Main Business Overview
    • 11.9.5 Lonza Latest Developments
  • 11.10 Abbott
    • 11.10.1 Abbott Company Information
    • 11.10.2 Abbott Bispecific Antibody Technology Platform Product Offered
    • 11.10.3 Abbott Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Abbott Main Business Overview
    • 11.10.5 Abbott Latest Developments
  • 11.11 Amgen
    • 11.11.1 Amgen Company Information
    • 11.11.2 Amgen Bispecific Antibody Technology Platform Product Offered
    • 11.11.3 Amgen Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 Amgen Main Business Overview
    • 11.11.5 Amgen Latest Developments
  • 11.12 Innovent
    • 11.12.1 Innovent Company Information
    • 11.12.2 Innovent Bispecific Antibody Technology Platform Product Offered
    • 11.12.3 Innovent Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Innovent Main Business Overview
    • 11.12.5 Innovent Latest Developments
  • 11.13 Epimab
    • 11.13.1 Epimab Company Information
    • 11.13.2 Epimab Bispecific Antibody Technology Platform Product Offered
    • 11.13.3 Epimab Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Epimab Main Business Overview
    • 11.13.5 Epimab Latest Developments
  • 11.14 Keymed
    • 11.14.1 Keymed Company Information
    • 11.14.2 Keymed Bispecific Antibody Technology Platform Product Offered
    • 11.14.3 Keymed Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.14.4 Keymed Main Business Overview
    • 11.14.5 Keymed Latest Developments
  • 11.15 Selexis
    • 11.15.1 Selexis Company Information
    • 11.15.2 Selexis Bispecific Antibody Technology Platform Product Offered
    • 11.15.3 Selexis Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.15.4 Selexis Main Business Overview
    • 11.15.5 Selexis Latest Developments
  • 11.16 SYNIMMUNE
    • 11.16.1 SYNIMMUNE Company Information
    • 11.16.2 SYNIMMUNE Bispecific Antibody Technology Platform Product Offered
    • 11.16.3 SYNIMMUNE Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.16.4 SYNIMMUNE Main Business Overview
    • 11.16.5 SYNIMMUNE Latest Developments
  • 11.17 F-star
    • 11.17.1 F-star Company Information
    • 11.17.2 F-star Bispecific Antibody Technology Platform Product Offered
    • 11.17.3 F-star Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.17.4 F-star Main Business Overview
    • 11.17.5 F-star Latest Developments
  • 11.18 Zymeworks Inc
    • 11.18.1 Zymeworks Inc Company Information
    • 11.18.2 Zymeworks Inc Bispecific Antibody Technology Platform Product Offered
    • 11.18.3 Zymeworks Inc Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.18.4 Zymeworks Inc Main Business Overview
    • 11.18.5 Zymeworks Inc Latest Developments
  • 11.19 Creative Biolabs
    • 11.19.1 Creative Biolabs Company Information
    • 11.19.2 Creative Biolabs Bispecific Antibody Technology Platform Product Offered
    • 11.19.3 Creative Biolabs Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.19.4 Creative Biolabs Main Business Overview
    • 11.19.5 Creative Biolabs Latest Developments
  • 11.20 ImmunoPrecise
    • 11.20.1 ImmunoPrecise Company Information
    • 11.20.2 ImmunoPrecise Bispecific Antibody Technology Platform Product Offered
    • 11.20.3 ImmunoPrecise Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.20.4 ImmunoPrecise Main Business Overview
    • 11.20.5 ImmunoPrecise Latest Developments
  • 11.21 CytomX Therapeutics, Inc.
    • 11.21.1 CytomX Therapeutics, Inc. Company Information
    • 11.21.2 CytomX Therapeutics, Inc. Bispecific Antibody Technology Platform Product Offered
    • 11.21.3 CytomX Therapeutics, Inc. Bispecific Antibody Technology Platform Revenue, Gross Margin and Market Share (2020-2022)
    • 11.21.4 CytomX Therapeutics, Inc. Main Business Overview
    • 11.21.5 CytomX Therapeutics, Inc. Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Bispecific Antibody Technology Platform. Industry analysis & Market Report on Bispecific Antibody Technology Platform is a syndicated market report, published as Global Bispecific Antibody Technology Platform Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Bispecific Antibody Technology Platform market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
2,898.72
5,797.44
3,381.84
6,763.68
553,721.40
1,107,442.80
305,134.20
610,268.40
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report